Q-omics provides the consensus-scored GALT profile across patient tissues and cancer cell-line models. GALT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, GALT is differentially expressed in 12, with the highest sampling consensus in BRCA. Additionally, GALT protein abundance shows 21,362 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, BRCA, and LSCC as cancer lineages where GALT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALT survival associations across molecular data types. GALT RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALT RNA expression–survival associations across cancer types. High GALT expression shows unfavorable associations in STAD, READ and MESO, but favorable associations in PAAD, KIRP and KIRC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for GALT RNA expression.
This table summarizes GALT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GALT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALT shows lower tumor expression in BRCA, LUAD, KICH, UCEC and KIRP and higher tumor expression in HNSC. The BRCA box plot shows higher GALT RNA expression in normal versus tumor tissue (log2 FC = −0.829, t-test p < 0.001).
This table shows molecular features associated with GALT in patient tissues and cancer cell lines. In patient samples, GALT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GALT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
